Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated ...
(PR-inside.com) First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial efficacy data expected in Q2 2027 FRAMINGHAM, MA / ACCESS Newswire / October 15, 2026 / Xenetic Bioscie…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


